home / stock / uncy / uncy quote
Last: | $0.5011 |
---|---|
Change Percent: | -3.18% |
Open: | $0.418 |
Close: | $0.5011 |
High: | $0.5013 |
Low: | $0.401 |
Volume: | 1,607,858 |
Last Trade Date Time: | 06/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.5011 | $0.418 | $0.5011 | $0.5013 | $0.401 | 1,607,858 | 06-28-2024 |
$0.4051 | $0.4819 | $0.4051 | $0.4827 | $0.339 | 3,376,693 | 06-27-2024 |
$0.48 | $0.4929 | $0.48 | $0.5073 | $0.4667 | 1,538,936 | 06-26-2024 |
$0.5 | $0.6292 | $0.5 | $0.6608 | $0.489 | 6,087,923 | 06-25-2024 |
$0.6827 | $0.6834 | $0.6827 | $0.777 | $0.68 | 3,499,530 | 06-24-2024 |
$0.6354 | $0.6367 | $0.6354 | $0.65 | $0.62 | 285,560 | 06-21-2024 |
$0.63 | $0.64 | $0.63 | $0.688 | $0.63 | 373,042 | 06-20-2024 |
$0.6458 | $0.6496 | $0.6458 | $0.6919 | $0.6249 | 505,459 | 06-19-2024 |
$0.6458 | $0.6496 | $0.6458 | $0.6919 | $0.6249 | 505,459 | 06-18-2024 |
$0.6503 | $0.66 | $0.6503 | $0.6602 | $0.641 | 399,097 | 06-17-2024 |
$0.6489 | $0.66 | $0.6489 | $0.662 | $0.6386 | 217,493 | 06-14-2024 |
$0.655 | $0.665 | $0.655 | $0.708 | $0.6509 | 139,229 | 06-13-2024 |
$0.6604 | $0.7 | $0.6604 | $0.7099 | $0.66 | 260,983 | 06-12-2024 |
$0.655 | $0.6433 | $0.655 | $0.6949 | $0.64 | 273,128 | 06-11-2024 |
$0.6386 | $0.8 | $0.6386 | $0.8 | $0.6061 | 911,981 | 06-10-2024 |
$0.7757 | $0.7856 | $0.7757 | $0.79766 | $0.7701 | 114,865 | 06-07-2024 |
$0.77 | $0.78 | $0.77 | $0.8 | $0.75 | 1,863,863 | 06-06-2024 |
$0.78 | $0.82 | $0.78 | $0.824 | $0.7777 | 346,838 | 06-05-2024 |
$0.8056 | $0.9004 | $0.8056 | $0.9171 | $0.7901 | 589,467 | 06-04-2024 |
$0.9063 | $0.9 | $0.9063 | $0.9598 | $0.895 | 659,053 | 06-03-2024 |
News, Short Squeeze, Breakout and More Instantly...
Unicycive Therapeutics Inc. Company Name:
UNCY Stock Symbol:
NASDAQ Market:
– Successfully Established Favorable Tolerability and Safety of OLC – – New Drug Application (NDA) Submission Anticipated in Q3 2024 – – Webcast and Conference Call Today at 8:30 A.M. ET – LOS ALTOS, Calif., June 25, 2024 (GLOBE NE...
– Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor – – Oral UNI-494 Shows Promise in a Preclinical Model as a Potential Candidate for Prevention of Delayed Graft Function Related to Acute Kidney Injury...
LOS ALTOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Ex...